Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Person

Per Kallblad

Tracked across 1 events · 6 articles · First seen Sep 22, 2026 · Last active Sep 22, 2026

Sentiment
10
Attention
1
Events
1
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
1 10
Tech
Bicara Therapeutics AB, a privately held Swedish precision medicine company, announced on September 22, 2026 the initiation of IND-enabling studies for BEA-17, its wholly owned, first-in-class oral degrader of the epigenetic regulators LSD1 and CoREST,…
Impact: As Chief Executive Officer of Bicara Therapeutics, Per Kallblad publicly framed the IND-enabling studies as a defining milestone for the BEA-17 programme. His role is communicative and leadership-oriented rather than directly market-moving.
Sep 22, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Per Kallblad live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.